Clinical Trial

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-16; most recent amendment 2025-12-24.
Status change: Not Yet Recruiting → Recruiting 2025-10-22
Trial Details
NCT Number NCT06942442
Lead Sponsor Sarcoma Alliance for Research through Collaboration
Collaborators: Royal Marsden NHS Foundation Trust, Memorial Sloan Kettering Cancer Center
Conditions HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
Enrollment 47 participants
Start Date 2025-10-22
Primary Completion 2030-10-01 (estimated)
Study Completion 2030-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-26